Revance Therapeutics RVNC has observed the following analyst ratings within the last quarter:

According to 5 analyst offering 12-month price targets in the last 3 months, Revance Therapeutics has an average price target of $30.6 with a high of $35.00 and a low of $24.00.

Below is a summary of how these 5 analysts rated Revance Therapeutics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock

This current average has increased by 33.04% from the previous average price target of $23.00.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Analyst Ratings: What Are They?

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

This article was generated by Benzinga's automated content engine and reviewed by an editor.